Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04172675




Registration number
NCT04172675
Ethics application status
Date submitted
20/11/2019
Date registered
21/11/2019
Date last updated
24/10/2024

Titles & IDs
Public title
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Scientific title
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions
Secondary ID [1] 0 0
2019-002449-39
Secondary ID [2] 0 0
CR108699
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urinary Bladder Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bladder - transitional cell cancer
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Erdafitinib
Treatment: Drugs - Investigator Choice (Gemcitabine)
Treatment: Drugs - Investigator Choice (Mitomycin C)

Experimental: Cohort 1: Erdafitinib - Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ \[CIS\], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy will receive treatment with erdafitinib.

Active comparator: Cohort 1: Investigators Choice - Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy will receive the investigator's choice of either intravesical gemcitabine or intravesical mitomycin C (MMC) or hyperthermic MMC. Participants who are randomized to gemcitabine or MMC or hyperthermic MMC in Cohort 1 and demonstrate a recurrence via investigator disease assessment will have the opportunity to cross over to treatment with erdafitinib.

Experimental: Cohort 2 - Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor will receive treatment with erdafitinib.

Experimental: Cohort 3 - Marker lesion study in intermediate-risk NMIBC presenting as papillary disease only. All enrolled participants will receive treatment with erdafitinib.


Treatment: Drugs: Erdafitinib
Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.

Treatment: Drugs: Investigator Choice (Gemcitabine)
Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.

Treatment: Drugs: Investigator Choice (Mitomycin C)
Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Recurrence-Free Survival (RFS)
Timepoint [1] 0 0
Up to 4 years
Secondary outcome [1] 0 0
Time to Progression
Timepoint [1] 0 0
Up to 4 years
Secondary outcome [2] 0 0
Overall Survival
Timepoint [2] 0 0
Up to 4 years
Secondary outcome [3] 0 0
Recurrence-Free Survival
Timepoint [3] 0 0
Months 6 and 12
Secondary outcome [4] 0 0
Plasma Concentration of Erdafitinib
Timepoint [4] 0 0
Cycle 1 Day 14, Cycle 2 Day 1 (each cycle is of 28 days)
Secondary outcome [5] 0 0
Number of Participants with Adverse events
Timepoint [5] 0 0
Up to 4 years

Eligibility
Key inclusion criteria
* Histologically confirmed, recurrent, non-muscle-invasive urothelial carcinoma of the bladder. Variant pathology are allowed
* Tumor with specified fibroblast growth factor receptor (FGFR) mutations or fusions
* Bacillus Calmette- Guerin (BCG)-unresponsive after adequate BCG therapy or BCG experienced participants
* Refuses or is not eligible for cystectomy (Cohort 1 and Cohort 2 only)
* Eastern Cooperative Oncology Group (ECOG) performance status Grade 0-1
* Must sign an informed consent form (ICF) (or their legally acceptable representative must sign) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
* A woman of childbearing potential must have a negative pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) (urine or serum) within 7 days before randomization (Cohort 1) or the first dose of study drug (Cohort 2 and Cohort 3)
* Adequate bone marrow, liver, and renal function as specified in the protocol
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Histologically confirmed, muscle-invasive (T2 or higher stage) urothelial carcinoma of the bladder
* Histopathology demonstrating any small cell component, pure adenocarcinoma, pure squamous cell carcinoma, or pure squamous CIS of the bladder
* Prior treatment with an FGFR inhibitor
* Active malignancies other than the disease being treated under study. The only allowed exceptions are: (a) skin cancer treated within the last 24 months that is considered completely cured (b) adequately treated lobular carcinoma in situ (LCIS) and ductal CIS (c) history of localized breast cancer and receiving antihormonal agents, or history of localized prostate cancer (N0M0) and receiving androgen deprivation therapy
* Current central serous retinopathy or retinal pigment epithelial detachment of any grade

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/02/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2025
Actual
Sample size
Target
Accrual to date
Final
107
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [2] 0 0
St Vincent s Hospital Sydney - Darlinghurst
Recruitment hospital [3] 0 0
Macquarie University - Macquarie University
Recruitment hospital [4] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
5042 - Bedford Park
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
2109 - Macquarie University
Recruitment postcode(s) [4] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Oregon
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Tennessee
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Washington
Country [16] 0 0
United States of America
State/province [16] 0 0
Wisconsin
Country [17] 0 0
Argentina
State/province [17] 0 0
Buenos Aires
Country [18] 0 0
Argentina
State/province [18] 0 0
Ciudad Autonoma de Buenos Aires
Country [19] 0 0
Argentina
State/province [19] 0 0
Ciudad Autonoma de
Country [20] 0 0
Argentina
State/province [20] 0 0
Cordoba
Country [21] 0 0
Belgium
State/province [21] 0 0
Gent
Country [22] 0 0
Belgium
State/province [22] 0 0
Leuven
Country [23] 0 0
Belgium
State/province [23] 0 0
Liege
Country [24] 0 0
Belgium
State/province [24] 0 0
Roeselare
Country [25] 0 0
Brazil
State/province [25] 0 0
Curitiba
Country [26] 0 0
Brazil
State/province [26] 0 0
Fortaleza
Country [27] 0 0
Brazil
State/province [27] 0 0
Goiania
Country [28] 0 0
Brazil
State/province [28] 0 0
Natal
Country [29] 0 0
Brazil
State/province [29] 0 0
Porto Alegre
Country [30] 0 0
Brazil
State/province [30] 0 0
Recife
Country [31] 0 0
Brazil
State/province [31] 0 0
Ribeirão Preto
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio de Janeiro
Country [33] 0 0
Brazil
State/province [33] 0 0
Santo Andre
Country [34] 0 0
Brazil
State/province [34] 0 0
Sao Paulo
Country [35] 0 0
Brazil
State/province [35] 0 0
São Paulo
Country [36] 0 0
China
State/province [36] 0 0
Nanjing
Country [37] 0 0
China
State/province [37] 0 0
Shanghai
Country [38] 0 0
China
State/province [38] 0 0
Wuhan
Country [39] 0 0
Czechia
State/province [39] 0 0
Brno
Country [40] 0 0
Czechia
State/province [40] 0 0
Liberec
Country [41] 0 0
Czechia
State/province [41] 0 0
Praha 2
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha 5
Country [43] 0 0
France
State/province [43] 0 0
Bordeaux
Country [44] 0 0
France
State/province [44] 0 0
Clermont Ferrand
Country [45] 0 0
France
State/province [45] 0 0
Lille
Country [46] 0 0
France
State/province [46] 0 0
Lyon Cedex 03
Country [47] 0 0
France
State/province [47] 0 0
Marseille Cedex 9
Country [48] 0 0
France
State/province [48] 0 0
Paris
Country [49] 0 0
France
State/province [49] 0 0
Poitiers
Country [50] 0 0
France
State/province [50] 0 0
Rennes Cedex
Country [51] 0 0
France
State/province [51] 0 0
Rouen
Country [52] 0 0
France
State/province [52] 0 0
Saint Gregoire
Country [53] 0 0
France
State/province [53] 0 0
Toulouse
Country [54] 0 0
France
State/province [54] 0 0
Vandœuvre-lès-Nancy Cedex
Country [55] 0 0
France
State/province [55] 0 0
Villejuif Cedex
Country [56] 0 0
Germany
State/province [56] 0 0
Duisburg
Country [57] 0 0
Germany
State/province [57] 0 0
Herne
Country [58] 0 0
Germany
State/province [58] 0 0
Lubeck
Country [59] 0 0
Germany
State/province [59] 0 0
Muenchen
Country [60] 0 0
Germany
State/province [60] 0 0
Muenster
Country [61] 0 0
Germany
State/province [61] 0 0
Mülheim an der Ruhr
Country [62] 0 0
Germany
State/province [62] 0 0
Nuernberg
Country [63] 0 0
Germany
State/province [63] 0 0
Nuertingen
Country [64] 0 0
Germany
State/province [64] 0 0
Wesseling
Country [65] 0 0
India
State/province [65] 0 0
Bangalore
Country [66] 0 0
India
State/province [66] 0 0
Delhi
Country [67] 0 0
India
State/province [67] 0 0
Lucknow
Country [68] 0 0
India
State/province [68] 0 0
Madhurai
Country [69] 0 0
India
State/province [69] 0 0
Nadiad
Country [70] 0 0
India
State/province [70] 0 0
Pune
Country [71] 0 0
Italy
State/province [71] 0 0
Acquaviva delle Fonti
Country [72] 0 0
Italy
State/province [72] 0 0
Aosta
Country [73] 0 0
Italy
State/province [73] 0 0
Cefalu
Country [74] 0 0
Italy
State/province [74] 0 0
Guastalla
Country [75] 0 0
Italy
State/province [75] 0 0
Lecce
Country [76] 0 0
Italy
State/province [76] 0 0
Macerata
Country [77] 0 0
Italy
State/province [77] 0 0
Milano
Country [78] 0 0
Italy
State/province [78] 0 0
Milan
Country [79] 0 0
Italy
State/province [79] 0 0
Napoli
Country [80] 0 0
Italy
State/province [80] 0 0
Roma
Country [81] 0 0
Italy
State/province [81] 0 0
Verona
Country [82] 0 0
Japan
State/province [82] 0 0
Bunkyo Ku
Country [83] 0 0
Japan
State/province [83] 0 0
Chiba
Country [84] 0 0
Japan
State/province [84] 0 0
Hakodate
Country [85] 0 0
Japan
State/province [85] 0 0
Hidaka
Country [86] 0 0
Japan
State/province [86] 0 0
Hitachi
Country [87] 0 0
Japan
State/province [87] 0 0
Kanagawa
Country [88] 0 0
Japan
State/province [88] 0 0
Nagoya
Country [89] 0 0
Japan
State/province [89] 0 0
Osaka
Country [90] 0 0
Japan
State/province [90] 0 0
Ota
Country [91] 0 0
Japan
State/province [91] 0 0
Takatsuki
Country [92] 0 0
Japan
State/province [92] 0 0
Tokyo
Country [93] 0 0
Japan
State/province [93] 0 0
Toyoake
Country [94] 0 0
Japan
State/province [94] 0 0
Tsukuba City
Country [95] 0 0
Japan
State/province [95] 0 0
Yokohama
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Busan
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Cheongju
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Daegu
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Goyang-si
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Jeollanam-do
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Seoul
Country [102] 0 0
Poland
State/province [102] 0 0
Gdansk
Country [103] 0 0
Poland
State/province [103] 0 0
Krakow
Country [104] 0 0
Poland
State/province [104] 0 0
Rzeszow
Country [105] 0 0
Poland
State/province [105] 0 0
Szczecin
Country [106] 0 0
Poland
State/province [106] 0 0
Warszawa
Country [107] 0 0
Poland
State/province [107] 0 0
Wroclaw
Country [108] 0 0
Spain
State/province [108] 0 0
Barcelona
Country [109] 0 0
Spain
State/province [109] 0 0
Madrid
Country [110] 0 0
Spain
State/province [110] 0 0
Sabadell
Country [111] 0 0
Spain
State/province [111] 0 0
Santander
Country [112] 0 0
Spain
State/province [112] 0 0
Valencia
Country [113] 0 0
Taiwan
State/province [113] 0 0
Kaohsiung
Country [114] 0 0
Taiwan
State/province [114] 0 0
Taichung
Country [115] 0 0
Taiwan
State/province [115] 0 0
Taipei
Country [116] 0 0
Taiwan
State/province [116] 0 0
Taoyuan County
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Manchester
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Sheffield
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Stevenage

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or fusions, and who recurred after bacillus calmette-guerin (BCG) therapy.
Trial website
https://clinicaltrials.gov/study/NCT04172675
Trial related presentations / publications
Han MA, Maisch P, Jung JH, Hwang JE, Narayan V, Cleves A, Hwang EC, Dahm P. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD009294. doi: 10.1002/14651858.CD009294.pub3.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04172675